Completed PHASE2 INTERVENTIONAL 2-arm NCT00755183

Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction

A Single-Center, Double-Masked, Randomized, Vehicle Controlled Study to Evaluate the Safety and Efficacy of Testosterone 0.03% Ophthalmic Solution Compared to Vehicle for the Treatment of Meibomian Gland Dysfunction

Sponsor: ORA, Inc.

Conditions Meibomian Gland Dysfunction

Interventions testosterone ophthalmic solution vehicle of testosterone ophthalmic solution

Updated 7 times since 2017 Last updated: Sep 29, 2020 Started: Jul 31, 2008 Primary completion: Apr 30, 2009 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00755183, this PHASE2 trial focuses on Meibomian Gland Dysfunction and remains completed. Sponsored by ORA, Inc., it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Nov 2020 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Nov 2020 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ORA, Inc.

Data source: ORA, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Andover, United States